contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


oncozenge-announces-uncertainty-regarding-payment-of-subscription-proceeds-and-liquidity-impact

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

OncoZenge

OncoZenge AB (publ) (the “Company”) has just been informed that the strategic investor Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”) will not be able to pay the subscription proceeds...

<div class="mfn-preamble"><p><strong>OncoZenge</strong><em><strong> AB (publ) (the “Company”) has just been informed that the strategic investor </strong></em><strong>Sichuan Yangtian Bio-Pharmaceutical Co, Ltd</strong><em><strong> (the “Investor”) will not be able to pay the subscription proceeds of approximately SEK 9.1 million by the end of the payment deadline in the directed share issue resolved by the Board of Directors of the Company and communicated on 19 December 2025.</strong></em></p></div><div class="mfn-body"><p><em>According to the preliminary information received by the Company, payment is expected to be made within approximately 30 days. As a result, the Company will not receive the expected proceeds within the anticipated timeframe. This means that the Company currently lacks sufficient liquidity to cover its obligations for the coming month.</em></p><p><em>The directed share issue constitutes the third of four tranches under the SEK 30.2 million investment undertaking pursuant to the investment agreement entered into by the Company and the Investor on 27 January 2025. All 1,400,894 shares have been formally subscribed for by the Investor and allotted by the Board of Directors.</em></p><p><em>The Company will inform the market once further information has been received from the Investor and the implications for the Company have been assessed. In the meantime, the Company is actively exploring available options to address the liquidity situation and to secure short-term financing. Further information will be communicated.</em></p></div><div class="mfn-footer mfn-c36bd55b4ec2"><p><strong class="mfn-heading-1">BupiZenge™ - Potential to be the leading treatment for oral pain.</strong><br> </p></div><div class="mfn-footer mfn-163a9926e483"><p><strong class="mfn-heading-1">Contacts</strong><br>Stian Kildal CEO Mobile: +46 76 115 3797 E-mail: stian.kildal@oncozenge.se<br>Michael Owens CFO Mobile: +46 73 324 4988 E-mail: michael.owens@oncozenge.se</p></div><div class="mfn-footer mfn-ba6514542f1c"><p><strong class="mfn-heading-1">About</strong><br>OncoZenge AB (publ) is a clinical-stage pharmaceutical company developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options are insufficient, such as oral mucositis from cancer therapy. Its lead candidate, BupiZenge™, represents a novel formulation of bupivacaine in a lozenge form, aimed at providing rapid and sustained local pain relief without the risks associated with systemic opioids. OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ. For more information, please visit <strong><a rel="noopener" href="http://www.oncozenge.se/">www.oncozenge.se</a></strong>.</p><p><strong>OncoZenge AB</strong><br>Gustavslundsvägen 34, 167 51 Stockholm, Sweden</p><p><strong>Certified Adviser</strong><br>OncoZenge's Certified Adviser is Redeye AB.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that OncoZenge is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-21 17:32 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/23747b94-69f8-44bc-83e5-f2d9f11da357/oncozenge-announces-uncertainty-regarding-payment-of-subscription-proceeds-and-liquidity-impact.pdf" class="mfn-generated mfn-primary">OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact</a></p></div>

OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact